Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 5, 2011, Pages 1354-1358

  Hughes, Adam D ^a   Chin, Kay H ^a   Dunham, Sarah L ^a   Jasper, Jeffrey R ^a   King, Kristin E ^a   Lee, Tae Weon ^a   Mammen, Mathai ^a   Martin, Jerri ^a   Steinfeld, Tod ^a  

^a THERAVANCE INC   (United States)

Author keywords

Beta 2 adrenoceptor agonist; Bronchodilator; COPD; Dual pharmacology; Inhaled; LABA; LAMA; MABA; Multivalent approach; Muscarinic acetylcholine receptor antagonist

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; MUSCARINIC M3 RECEPTOR ANTAGONIST;

ARTICLE; DRUG BINDING SITE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; MUSCARINIC ANTAGONISTS; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, MUSCARINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79951727504     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.043     Document Type: Article

References (39)

1. R.A. Pauwels, and K.F. Rabe Lancet 364 2004 613
2. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Executive Summary updated 2007.
3. P.M.A. Calverley, J.A. Anderson, C. Bartolome, G.T. Ferguson, C. Jenkins, P.W. Jones, J.C. Yates, and J. Vestbo N. Eng. J. Med. 356 2007 775
4. P. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. Pride, A. Gulsvik, J. Anderson, and C. Maden Lancet 361 2003 449 Erratum: Lancet, 2003, 361, 1660
5. P.M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, and H. Olsson Eur. Respir. J. 22 2003 912
6. COMBIVENT Inhalation Aerosol Study Group Chest 105 1994 1411
7. COMBIVENT Inhalation Solution Study Group Chest 112 1997 1514
8. N.J. Gross N. Eng. J. Med. 319 8 1988 486
9. R.C. Ahrens, and G.D. Smith Pharmacotherapy 4 1984 105
10. N.A. Reynolds, C.M. Perry, and G.M. Keating Drugs 64 2004 431
11. M. Johnson Med. Res. Rev. 15 1995 225
12. C.M. Spencer, and B. Jarvis Drugs 57 1999 933
13. N.A. Reynolds, K.A. Lyseng-Williamson, and L.R. Wiseman Drugs 65 2005 1715
14. G.M. Keating, and P.L. McCormack Drugs 67 2007 2383
15. T.T. Hansel, and P.J. Barnes Drugs Today 38 2002 585
16. S.L. Davies, and J. Castañer Drugs Future 30 2005 1219
17. Structure and SAR recently reported: P.A. Procopiou, V.J. Barrett, N.J. Bevan, K. Biggadike, P.C. Box, P.R. Butchers, D.M. Coe, R. Conroy, A. Emmons, A.J. Ford, D.S. Holmes, H. Horsley, F. Kerr, A.-M. Li-Kwai-Cheung, B.E. Looker, I.S. Mann, I.M. McLay, V.S. Morrison, P.J. Mutch, C.E. Smith, and P. Tomlin J. Med. Chem. 53 2010 4522
18. M. Cazzola, and M.G. Matera Br. J. Pharm. 155 2008 291 Aclidinium bromide was previously in trials as a once daily LAMA, however it is now being evaluated in Phase 3 trials as a twice daily product
19. J.A. van Noord, J.-L. Aumann, E. Janssens, J.J. Smeets, J. Verhaert, B. Disse, A. Mueller, and P.J.G. Cornelissen Eur. Respir. J. 26 2005 214
20. M. Cazzola, F. Di Marco, P. Santus, B. Boveri, M. Verga, M.G. Matera, and S. Centanni Pulm. Pharmacol. Ther. 17 2004 35
21. J.A. van Noord, J-L. Aumann, E. Janssens, J.J. Smeets, J. Zaagsma, A. Mueller, and P.J.G. Cornelissen Respir. Med. 104 2010 995
22. C. Lee, and J. Corren Expert Rev. Respir. Med. 2 2008 551
23. Clinical trials investigating the combination of a LAMA (NVA237) and LABA (Indacaterol) are reported on the websites of Novartis and Sosei.
24. Hughes, A. D.; Chin, K. H.; Hegde, S. S.; Husfeld, C. O.; Jasper, J. R.; Ji, Y.; King, K. E.; Lee, T. W.; Li, L.; Mammen, M.; McNamara, A. J.; Mischki, T. K.; Obedencio, G. P.; Pulido-Rios, T.; Steinfeld, T.; Sweazey, S. M.; Wilson, R. D. Abstracts of Papers, 234th National Meeting of the American Chemical Society, Boston, MA, Aug 19-23, 2007; American Chemical Society: Washington, DC; MEDI-023.
25. T. Steinfeld, M. Mammen, J.A. Smith, R.D. Wilson, and J.R. Jasper Mol. Pharmacol. 72 2007 291
26. Findings from Theravance's LABA program will be reported at a later date.
27. 'Biphenyl compounds useful as muscarinic receptor antagonists', Mammen, M.; Ji, Y.-H.; Mu, Y.; Mischki, T.; Malathong, V. U.S. Patent 7,456,199, 2008.
28. R. Naito, M. Takeuchi, K. Morihira, M. Hayakawa, K. Ikeda, T. Shibanuma, and Y. Isomura Chem. Pharm. Bull. 46 1998 1286
29. All yields are unoptimized. Final step yields in each scheme refer to isolated compounds after purification by reverse phase preparative HPLC.
30. 50 values according to Cheng, Y.; Prusoff, W. H. Biochem. Pharmacol. 1973, 22, 3099. Muscarinic acetylcholine receptor antagonist behavior has previously been reported in our patent publications and confirmed in our in vivo models.
31. 50 values according to Cheng, Y.; Prusoff, W. H. Biochem. Pharmacol. 1973, 22, 3099.
32. 50 values.
33. Reference for compounds 12, 15, 25 (carbostyril building blocks): 'Crystalline form of a biphenyl compound', Chao, R. S.; Rapta, M.; Colson, P.-J. U.S. Patent 7,521,558, 2009.
34. 2 adrenergic receptor agonist and muscarinic receptor antagonist activity', Colson, P.-J.; Hughes, A. D.; Husfeld, C.; Mammen, M.; Rapta, M. U.S. Patent 7,524,965, 2007.
35. Saligenin and glyoxal reference: 'Biphenyl derivatives', Mammen, M.; Dunham, S.; Hughes, A.; Lee, T. W.; Husfeld, C.; Stangeland, E. U.S. Patent 7,141,671, 2006.
36. 'Substituted pyrrolidine and related compounds', Mammen, M.; Hughes, A. D.; Ji, Y.-H.; Li, L.; Zhang, W. U.S. Patent 7, 351, 718, 2008.
37. 'Azabicycloalkane compounds', Mammen, M.; Hughes, A. D. U.S. Patent 7, 358, 244, 2008.
38. L.H. Jones, H. Baldock, M.E. Bunnage, J. Burrows, N. Clarke, M. Coghlan, D. Entwistle, D. Fairman, N. Feeder, C. Fulton, L. Hilton, K. James, R.M. Jones, A.S. Kenyon, S. Marshall, S.D. Newman, R. Osborne, S. Patel, M.D. Selby, E.F. Stuart, M.A. Trevethick, K.N. Wright, and D.A. Price Bioorg. Med. Chem. Lett. 2010 doi:10.1016/j.bmcl.2010.10.132
39. T. Steinfeld, A.D. Hughes, U. Klein, J.A.M. Smith, and M. Mammen Mol. Pharmacol. 2010 doi:10.1124/mol.110.069120